Ethyl 5-Aminobenzo[b]furan-2-Carboxylate Vilazodone API Precursor Specs
Validating Ethyl 5-Aminobenzo[b]furan-2-Carboxylate Melting Point 54-56°C Against TCI America E11381G Specifications
For R&D managers and procurement specialists evaluating Ethyl 5-Aminobenzo[b]furan-2-Carboxylate (CAS: 174775-48-5), physical constants serve as the primary indicator of identity and initial purity. The accepted melting point range for this benzofuran derivative is 54-56°C. When benchmarking against commercial references such as the TCI America E11381G specification, consistency in this thermal transition is critical. Deviations outside this narrow window often indicate the presence of homologous impurities or residual solvents that co-crystallized during the final purification step.
From a process engineering perspective, relying solely on the melting point is insufficient for high-stakes API synthesis. A non-standard parameter we monitor closely is the thermal degradation threshold during prolonged exposure to temperatures just below the melting point. While the material remains solid at ambient conditions, we have observed that trace amine oxidation can occur if storage temperatures fluctuate near 45°C for extended periods. This manifests as a subtle color drift from white to pale yellow, which is not always captured in a standard visual inspection but can affect the kinetics of the subsequent piperazine coupling reaction. Ensuring the material maintains its crystalline integrity without undergoing premature thermal stress is essential for maintaining reaction reproducibility.
Defining High-Purity Grades and Impurity Profiles for Vilazodone API Precursor Synthesis
As a key pharmaceutical intermediate in the production of Vilazodone, the impurity profile of Ethyl 5-Aminobenzo[b]furan-2-Carboxylate directly impacts the purification load of the final Active Pharmaceutical Ingredient. The synthesis route typically involves coupling this benzofuran core with a piperazine-indole fragment. Therefore, specific attention must be paid to residual starting materials, such as unreacted nitro-reduction precursors or over-alkylated byproducts.
At NINGBO INNO PHARMCHEM CO.,LTD., we classify grades based on the intended stage of drug development. For clinical trial supply, tighter controls on genotoxic impurities are required compared to early-stage research chemical applications. The target industrial purity is typically ≥98%, with total impurities kept below 2.0%. However, the identity of those impurities matters more than the aggregate percentage. For example, isomers that are difficult to separate during the final API crystallization must be minimized at this precursor stage. You can review detailed technical data for our Ethyl 5-Aminobenzo[b]furan-2-Carboxylate 174775-48-5 to understand how we manage these profiles.
Essential COA Parameters: HPLC Assay, Residual Solvents, and Batch-to-Batch Consistency
Quality assurance in organic synthesis relies on rigorous analytical data. A comprehensive Certificate of Analysis (COA) for this API precursor must extend beyond simple identity confirmation. The following table outlines the critical technical parameters that should be validated for every batch intended for GMP-aligned synthesis:
| Parameter | Test Method | Typical Specification | Criticality |
|---|---|---|---|
| Assay (HPLC) | Area Normalization | ≥ 98.0% | High |
| Melting Point | Capillary Method | 54-56°C | High |
| Water Content (KF) | Karl Fischer | ≤ 0.5% | Medium |
| Residual Solvents | GC Headspace | Compliant with ICH Q3C | High |
| Appearance | Visual | White to Off-White Solid | Medium |
Batch-to-batch consistency is the primary challenge in scaling organic synthesis processes. Variations in residual solvent profiles, particularly polar aprotic solvents used in the esterification step, can influence the solubility of the intermediate in downstream reactors. We recommend requesting chromatograms alongside the COA to verify the absence of late-eluting impurities that might accumulate in recycled solvent streams.
Bulk Packaging Standards and Stability Data for Ethyl 5-Aminobenzo[b]furan-2-Carboxylate
Logistics and physical packaging play a vital role in maintaining chemical stability during transit. Ethyl 5-Aminobenzo[b]furan-2-Carboxylate is typically supplied in 25kg cardboard drums with double polyethylene liners to ensure moisture protection. For larger volume requirements, customized packaging solutions are available to suit specific warehouse constraints. It is imperative to store the material in a cool, dry place, away from strong light and heat sources.
Stability data indicates that the compound remains stable for 24 months when stored under recommended conditions in unopened containers. However, once opened, the material should be used promptly or re-sealed under inert gas to prevent oxidative degradation. We focus strictly on physical packaging integrity and factual shipping methods to ensure the product arrives in specification. Environmental certifications or regulatory compliance claims regarding transport are subject to specific carrier capabilities and destination regulations, so please refer to the batch-specific COA and shipping documentation for each order.
Aligning Precursor Specifications with Vilazodone Hydrochloride ANDA Generic Entry Requirements
For manufacturers targeting Abbreviated New Drug Application (ANDA) approval for Vilazodone Hydrochloride, the quality of the starting material is scrutinized during regulatory filing. Data from approved drug variants shows that Vilazodone Hydrochloride formulations often contain excipients such as Microcrystalline Cellulose, Lactose Monohydrate, and Croscarmellose Sodium. While these excipients define the final tablet properties, the purity of the API itself depends heavily on the precursor quality.
Generic entry requirements demand that the API manufacturer demonstrates control over the synthesis pathway. This includes validating that the Ethyl 5-Aminobenzofuran-2-Carboxylate used does not introduce persistent impurities that survive the final purification steps. Understanding the excipient profile of competitors, such as those using Ferric Oxide Red or specific colorants, helps in reverse-engineering the formulation stability. However, the core focus remains on the chemical identity of the API precursor. Ensuring the precursor meets strict spectral data requirements (NMR, IR, MS) aligns the supply chain with the rigorous documentation needed for successful generic market entry.
Frequently Asked Questions
What is the typical lead time for bulk orders of this intermediate?
Lead times vary based on current inventory levels and production scheduling. Please contact our sales team for a specific timeline related to your required volume.
Can you provide stability data for storage above 25°C?
Standard stability data is generated at recommended storage conditions. For deviations above 25°C, please refer to the batch-specific COA or request accelerated stability study results from our technical team.
Is the material supplied suitable for GMP manufacturing?
We supply materials suitable for various stages of development. For GMP manufacturing, specific quality agreements and audits are required to ensure compliance with your internal standards.
What documentation accompanies a standard shipment?
Standard shipments include a Certificate of Analysis (COA) and a Safety Data Sheet (SDS). Additional regulatory documentation may be available upon request.
Sourcing and Technical Support
Securing a reliable supply chain for critical pharmaceutical intermediates requires a partner with deep technical expertise and robust manufacturing capabilities. Our team is equipped to handle inquiries regarding custom synthesis, scale-up feasibility, and technical specifications for complex benzofuran derivatives. We prioritize transparency in our commercial terms and technical specs to facilitate smooth procurement processes for R&D and production units. To request a batch-specific COA, SDS, or secure a bulk pricing quote, please contact our technical sales team.